Status:
COMPLETED
Fondaparinux EU-RMP (Adherence)
Lead Sponsor:
GlaxoSmithKline
Conditions:
Acute Coronary Syndrome
Eligibility:
All Genders
Brief Summary
Fondaparinux, a synthetic and specific factor Xa inhibitor, was granted an ACS indication by Health Canada in March 2007 and by the EMEA in September 2007. Among ACS patients, fondaparinux is indicate...
Eligibility Criteria
Inclusion
- Discharge diagnosis of ACS (UA/NSTEMI or STEMI)
- PCI during the hospitalization
- Anticoagulant treatment with fondaparinux
Exclusion
- Enrollment at the time of the index hospitalization in a clinical study that could influence ACS treatment practices, specifically the in-hospital use of anticoagulation
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01406301
Start Date
March 1 2008
End Date
July 1 2011
Last Update
April 27 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.